Stem Cell Revival: The 1990s are Back
By New Scientist,
New Scientist
| 04. 30. 2014
"SINCE what works in sheep is likely to be possible in humans, we are suddenly propelled right past the imagined techniques of Brave New World." That was how New Scientist greeted the news, in March 1997, of the creation of Dolly the cloned sheep.
It has taken longer than expected. More than 17 years later, what worked in sheep finally appears to be working in humans (see "Insulin-making cells created by Dolly-cloning method"). This is a potentially major medical breakthrough, but no longer feels as challenging as it once did. In fact, after endless hope, hype and failure, it is hard to feel there is anything brave or new in this line of research.
To say stem cell science has a chequered past would be an understatement. Those with long memories will recall that South Korea's fallen stem-cell hero Woo Suk Hwang falsely claimed to have replicated the Dolly technique in humans in 2005.
Controversy has dogged the field ever since. Because the Dolly technique involves the destruction of human embryos, its ethical dimensions have been...
Related Articles
By Emma McDonald Kennedy
| 10.29.2026
At the beginning of Nathan Fielder and Lance Oppenheim’s blockbuster documentary You Can See Everything, Billy Evans (partner of Theranos founder and convicted fraudster Elizabeth Holmes), says that they decided to do the film for one purpose: “radical transparency.” As they work on “Theranos 2.0,” Evans and Holmes want to show the public that she has been misunderstood –– painted as a liar and a fraud in the public imagination (and the courts) despite, as she claims in the...
By Charles Schmidt, Undark | 09.25.2026
In 2010, scientists at the University of Tokyo and other institutions reported a startling achievement: They had successfully grown a pancreas made almost entirely of rat cells within the bodies of mice. The research was directed by Hiromitsu Nakauchi, a...
By Editors, Nature | 08.18.2026
Shinya Yamanaka doesn’t see himself as a celebrity. But people do recognize the stem-cell researcher when he’s out for a run, often while training for a marathon, on the streets of Kyoto, Japan.
Many of them call out words of...
By Jessica Hamzelou, MIT Technology Review | 07.30.2026
As of this week in Montana, any biotech company with an experimental drug has a clear path to selling it to consumers. Companies whose drugs have been through preliminary testing—sometimes in as few as 10 healthy people—can pay $12,500 to...